Trio of firsts arrive with one tick

Posted 13 January 2025 PM

Melbourne-based Mesoblast has much to look forward to in 2025, having received an early Christmas present from the FDA, which gave the nod to a treatment with a trio of firsts.

The FDA approved Mesoblast's Ryoncil to treat steroid-refractory acute graft versus host disease in pediatric patients two months and older. It's Mesoblast's first approved therapy, the first FDA-approved therapy for children with SR-aGvHD, and the first mesenchymal stromal cell (MSC) therapy approved by the FDA.

To see the whole article, please login